Evaluation of animal models for intestinal first-pass metabolism of drug candidates to be metabolized by CYP3A enzymes via in vivo and in vitro oxidation of midazolam and triazolam

J. Kuze, T. Mutoh, T. Takenaka, N. Oda, N. Hanioka, S. Narimatsu

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

1. To search an appropriate evaluation methodology for the intestinal first-pass metabolism of new drug candidates, grapefruit juice (GFJ)-and vehicle (tap water)-pretreated mice or rats were orally administered midazolam (MDZ) or triazolam (TRZ), and blood levels of the parent compounds and their metabolites were measured by liquid chromatography/MS/MS. A significant effect of GFJ to elevate the blood levels was observed only for TRZ in mice. 2. In vitro experiments using mouse, rat and human intestinal and hepatic microsomal fractions demonstrated that GFJ suppressed the intestinal microsomal oxidation of MDZ and especially TRZ. Substrate inhibition by MDZ caused reduction in 1′-hydroxylation but not 4-hydroxylation in both intestinal and hepatic microsomal fractions. The kinetic profiles of MDZ oxidation and the substrate inhibition in mouse intestinal and hepatic microsomal fractions were very similar to those in human microsomes but were different from those in rat microsomes. Furthermore, MDZ caused mechanism-based inactivation of cytochrome P450 3A-dependent TRZ 1′-hydroxylation in mouse, rat and human intestinal microsomes with similar potencies. 3. These results are useful information in the analysis of data obtained in mouse and rat for the evaluation of first-pass effects of drug candidates to be metabolized by CYP3A enzymes.

Original languageEnglish
Pages (from-to)598-606
Number of pages9
JournalXenobiotica
Volume43
Issue number7
DOIs
Publication statusPublished - Jun 2013

Fingerprint

Triazolam
Cytochrome P-450 CYP3A
Midazolam
Metabolism
Rats
Animals
Animal Models
Hydroxylation
Citrus paradisi
Oxidation
Enzymes
Microsomes
Pharmaceutical Preparations
Blood
Liver
Liquid chromatography
Substrates
Metabolites
Liquid Chromatography
In Vitro Techniques

Keywords

  • CYP3A
  • Human
  • Intestinal first-pass metabolism
  • Mechanism-based inactivation
  • Midazolam
  • Mouse
  • Rat
  • Substrate inhibition
  • Triazolam

ASJC Scopus subject areas

  • Pharmacology
  • Toxicology
  • Biochemistry
  • Health, Toxicology and Mutagenesis

Cite this

Evaluation of animal models for intestinal first-pass metabolism of drug candidates to be metabolized by CYP3A enzymes via in vivo and in vitro oxidation of midazolam and triazolam. / Kuze, J.; Mutoh, T.; Takenaka, T.; Oda, N.; Hanioka, N.; Narimatsu, S.

In: Xenobiotica, Vol. 43, No. 7, 06.2013, p. 598-606.

Research output: Contribution to journalArticle

@article{9d1c5932322e4cd99a578263fb7e4795,
title = "Evaluation of animal models for intestinal first-pass metabolism of drug candidates to be metabolized by CYP3A enzymes via in vivo and in vitro oxidation of midazolam and triazolam",
abstract = "1. To search an appropriate evaluation methodology for the intestinal first-pass metabolism of new drug candidates, grapefruit juice (GFJ)-and vehicle (tap water)-pretreated mice or rats were orally administered midazolam (MDZ) or triazolam (TRZ), and blood levels of the parent compounds and their metabolites were measured by liquid chromatography/MS/MS. A significant effect of GFJ to elevate the blood levels was observed only for TRZ in mice. 2. In vitro experiments using mouse, rat and human intestinal and hepatic microsomal fractions demonstrated that GFJ suppressed the intestinal microsomal oxidation of MDZ and especially TRZ. Substrate inhibition by MDZ caused reduction in 1′-hydroxylation but not 4-hydroxylation in both intestinal and hepatic microsomal fractions. The kinetic profiles of MDZ oxidation and the substrate inhibition in mouse intestinal and hepatic microsomal fractions were very similar to those in human microsomes but were different from those in rat microsomes. Furthermore, MDZ caused mechanism-based inactivation of cytochrome P450 3A-dependent TRZ 1′-hydroxylation in mouse, rat and human intestinal microsomes with similar potencies. 3. These results are useful information in the analysis of data obtained in mouse and rat for the evaluation of first-pass effects of drug candidates to be metabolized by CYP3A enzymes.",
keywords = "CYP3A, Human, Intestinal first-pass metabolism, Mechanism-based inactivation, Midazolam, Mouse, Rat, Substrate inhibition, Triazolam",
author = "J. Kuze and T. Mutoh and T. Takenaka and N. Oda and N. Hanioka and S. Narimatsu",
year = "2013",
month = "6",
doi = "10.3109/00498254.2012.751517",
language = "English",
volume = "43",
pages = "598--606",
journal = "Xenobiotica",
issn = "0049-8254",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - Evaluation of animal models for intestinal first-pass metabolism of drug candidates to be metabolized by CYP3A enzymes via in vivo and in vitro oxidation of midazolam and triazolam

AU - Kuze, J.

AU - Mutoh, T.

AU - Takenaka, T.

AU - Oda, N.

AU - Hanioka, N.

AU - Narimatsu, S.

PY - 2013/6

Y1 - 2013/6

N2 - 1. To search an appropriate evaluation methodology for the intestinal first-pass metabolism of new drug candidates, grapefruit juice (GFJ)-and vehicle (tap water)-pretreated mice or rats were orally administered midazolam (MDZ) or triazolam (TRZ), and blood levels of the parent compounds and their metabolites were measured by liquid chromatography/MS/MS. A significant effect of GFJ to elevate the blood levels was observed only for TRZ in mice. 2. In vitro experiments using mouse, rat and human intestinal and hepatic microsomal fractions demonstrated that GFJ suppressed the intestinal microsomal oxidation of MDZ and especially TRZ. Substrate inhibition by MDZ caused reduction in 1′-hydroxylation but not 4-hydroxylation in both intestinal and hepatic microsomal fractions. The kinetic profiles of MDZ oxidation and the substrate inhibition in mouse intestinal and hepatic microsomal fractions were very similar to those in human microsomes but were different from those in rat microsomes. Furthermore, MDZ caused mechanism-based inactivation of cytochrome P450 3A-dependent TRZ 1′-hydroxylation in mouse, rat and human intestinal microsomes with similar potencies. 3. These results are useful information in the analysis of data obtained in mouse and rat for the evaluation of first-pass effects of drug candidates to be metabolized by CYP3A enzymes.

AB - 1. To search an appropriate evaluation methodology for the intestinal first-pass metabolism of new drug candidates, grapefruit juice (GFJ)-and vehicle (tap water)-pretreated mice or rats were orally administered midazolam (MDZ) or triazolam (TRZ), and blood levels of the parent compounds and their metabolites were measured by liquid chromatography/MS/MS. A significant effect of GFJ to elevate the blood levels was observed only for TRZ in mice. 2. In vitro experiments using mouse, rat and human intestinal and hepatic microsomal fractions demonstrated that GFJ suppressed the intestinal microsomal oxidation of MDZ and especially TRZ. Substrate inhibition by MDZ caused reduction in 1′-hydroxylation but not 4-hydroxylation in both intestinal and hepatic microsomal fractions. The kinetic profiles of MDZ oxidation and the substrate inhibition in mouse intestinal and hepatic microsomal fractions were very similar to those in human microsomes but were different from those in rat microsomes. Furthermore, MDZ caused mechanism-based inactivation of cytochrome P450 3A-dependent TRZ 1′-hydroxylation in mouse, rat and human intestinal microsomes with similar potencies. 3. These results are useful information in the analysis of data obtained in mouse and rat for the evaluation of first-pass effects of drug candidates to be metabolized by CYP3A enzymes.

KW - CYP3A

KW - Human

KW - Intestinal first-pass metabolism

KW - Mechanism-based inactivation

KW - Midazolam

KW - Mouse

KW - Rat

KW - Substrate inhibition

KW - Triazolam

UR - http://www.scopus.com/inward/record.url?scp=84878860831&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878860831&partnerID=8YFLogxK

U2 - 10.3109/00498254.2012.751517

DO - 10.3109/00498254.2012.751517

M3 - Article

C2 - 23282066

AN - SCOPUS:84878860831

VL - 43

SP - 598

EP - 606

JO - Xenobiotica

JF - Xenobiotica

SN - 0049-8254

IS - 7

ER -